Seeking Patent Reform in Europe - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Seeking Patent Reform in Europe


ePT--the Electronic Newsletter of Pharmaceutical Technology

The European Generic Medicines Association (EGA) is calling for a reform of the European patent system. The agency stresses that the quality of patent examinations and applications should be improved, and that examination and opposition proceedings should be accelerated.

Speaking at the sixth EGA legal-affairs forum held in Munich last week, Greg Perry, director general of the EGA, said, "If the patent system is not reformed in Europe, drug manufacturers will encounter increasing hurdles to competition and real innovation."

The importance of the patent system was highlighted in the European Commission's Pharmaceutical Sector Inquiry, which was launched in 2008 to determine why few novel medicines were being brought to market. The final report, released in 2009, called for the strengthening of the European patent system and also suggested the establishment of a single European patent. Both views were supported by the European Patent Office (EPO), which has been trying to "raise the bar" to help end patent uncertainty.

In a press statement, the EGA said that it supports the EPO's efforts and also backs the introduction of an Information Disclosure Statement, a requirement for applicants to provide the results of earlier relevant patent office searches to aid the European examination procedure.

EGA remains concerned about some issues, however. First, the agency is worried about the possibility of evading EPO rules that limit the filing of divisional applications. Second, the EGA adds that patent litigation discrepancies across Europe are problematic. "This disparity could be solved by the establishment of a well-balanced, central European Patent Court with technically qualified experienced judges," said the press statement. "This would create an opportunity to streamline and simplify patent disputes."

Following on from the inquiry, the EGA has said that it will continue dialogue with the EPO with the aim of improving the efficiency of the patent system in line with proposals from the European Commission.

"The follow up to the Pharmaceutical Sector inquiry is now clearly taking place. Recent moves by the European Commission's DG competition to investigate actions that hinder the market entry of generic citalopram and Spain's move to accelerate pricing decisions for generic medicines are evidence of this," said Perry.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here